$MDT

Walter Matthew R. sold $258K of MDT

Walter Matthew R. (SVP, Chief HR Officer) sold 3,102 shares of Medtronic plc (MDT) at $83.15 ($0.26M total) on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Walter Matthew R.
Published Jul 9, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

The disclosed sale is a concrete datapoint for insider activity, but it does not introduce new company-specific fundamentals (no guidance, trial, deal, or regulatory action).

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable for directional fundamental trades.

03

What to watch

The article does not state whether sales were part of a broader pattern, nor does it provide options activity or other holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 2/10Timing: new Form 4 filed July 9, covering a July 8 sale

Background

This is an SEC Form 4 insider transaction disclosure for Medtronic plc, reported as an open-market sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic insider Walter Matthew R., SVP Chief HR Officer, sold 3,102 shares for about $257,931 under a 10b5-1 plan on July 8.

Expected impact

Likely minimal impact on MDT price; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or financial catalyst.

Market effects

No clear read-across to medtech sector fundamentals from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can reflect personal liquidity needs or risk management, which some traders may still fade.

Key entities

  • Medtronic plc

    MDT, subject of the Form 4 insider transaction disclosure.

  • Walter Matthew R.

    SVP, Chief HR Officer who sold 3,102 shares on July 8 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.